December 2, 2009
Genta to Support Initiation of New Clinical Trial using Ganite® as Treatment for Life-Threatening Infections in Patients with Cystic Fibrosis
November 16, 2009
Genta Announces Third Quarter 2009 Financial Results and Restructuring to Focus on Core Oncology Initiatives
November 10, 2009
Genta Incorporated to Present at the Lazard Capital Markets
November 4, 2009
Genta Incorporated to Host Conference Call to Discuss Third Quarter 2009 Financial Results and Operational Priorities on November 16, 2009
October 28, 2009
Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense® in Patients with Advanced Melanoma
October 28, 2009
Genta Incorporated Announces Conference Call to Review Top-Line Results of AGENDA Phase 3 Trial of Genasense® in Patients with Advanced Melanoma
September 4, 2009
Genta Announces Closing of $10 Million in Two Offerings of Common Stock and Convertible Notes
September 2, 2009
Genta Incorporated to Present at the Rodman & Renshaw Annual Global Investment Conference
August 24, 2009
Genta Announces Webcast of 2009 Annual Shareholders Meeting
August 14, 2009
Genta Incorporated Announces Second Quarter 2009 Financial Results
August 10, 2009
Genta Incorporated to Host Conference Call to Discuss Second Quarter 2009 Highlights and Financial Results
July 14, 2009
New Publication Confirms Critical Link of LDH Biomarker in Genasense® Trials to Overall Survival in Advanced Melanoma
July 13, 2009
Genta Implements Reverse Stock Split
July 7, 2009
Genta Raises $10 Million in Offering of Common Stock and Convertible Notes
June 29, 2009
Genta Incorporated Announces Delay in Implementation of Reverse Common Stock Split
June 26, 2009
Board of Directors of Genta Incorporated Announce Reverse Split of Company's Common Stock
June 3, 2009
Genasense® Combined with Temodar® and Abraxane® Shows Preliminary Evidence of High Response Rates and Extended Survival in Patients with Advanced Melanoma
June 1, 2009
New Clinical Data for Tesetaxel, a Leading Oral Taxane, Show Anticancer Activity and Acceptable Safety in Ongoing Study
May 28, 2009
Genta Incorporated Announces Record Date and Meeting Date for Special Stockholders Meeting
May 26, 2009
Genta Incorporated Announces Postponement of Special Stockholders Meeting
May 19, 2009
Independent Data Monitoring Board Recommends Continuation to Completion of Genta™s Phase 3 Trial of Genasense® in Advanced Melanoma
May 12, 2009
Genta Incorporated Announces First Quarter 2009 Financial Results
May 7, 2009
Genta Incorporated to Host Conference Call to Discuss First Quarter 2009 Highlights and Financial Results
April 29, 2009
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense® in Advanced Melanoma(2)
April 28, 2009
Genta Announces Allowance of Two Key European Patents for Genasense®
April 23, 2009
Genta Announces Presentations for Two Lead Compounds, Genasense® and Tesetaxel, at 2009 Annual ASCO Meeting
April 7, 2009
Genta Announces Completion of Patient Enrollment into Global Phase 3 Trial of Genasense® in Advanced Melanoma
April 2, 2009
Genta Secures Up to $12 Million in Convertible Debt Financing
March 6, 2009
FDA Appeal Decision Indicates that Genasense® Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Trial
February 13, 2009
Genta Incorporated Announces Fourth Quarter and Year End 2008 Financial Results and Corporate Highlights
February 11, 2009
Genta Submits Randomized Study of Tesetaxel in Patients with Advanced Gastric Cancer to FDA for Special Protocol Assessment
February 9, 2009
Genta Incorporated to Release Fourth Quarter Financial Results and Host Conference Call
February 2, 2009
Genta Incorporated to Present at the 11th Annual BIO CEO & Investor Conference
January 14, 2009
Genta Initiates New Clinical Trial of Tesetaxel, the Leading Oral Taxane in Clinical Development
January 12, 2009
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense® in Advanced Melanoma
January 8, 2009
Genta Announces Issuance of Two Key U.S. Patents for its Gallium Products Franchise
January 5, 2009
Genta Summarizes Phase 2 Activity and Receives Orphan Drug Designation in Gastric Cancer for Tesetaxel, a Leading Oral Taxane in Clinical Development
